2991567-27-0
Chemical Structure
HSP110-IN-1
- CAS No.: 2991567-27-0
- Formula:C29H32N4O5
- Molecular Weight:516.59
InChIKey: LCDZALKZCHXOTO-UHFFFAOYSA-N
SMILES: COC1=CC=C(C=C1OC)N2CC3CN(CC3C2)C4=C(C=C(C=N4)C5=CC(OC)=C(C(OC)=C5)OC)C#N
Biological Activity: HSP110-IN-1 is a HSP110 inhibitor. HSP110-IN-1 binds to HSP110, inhibits the activity of STAT3, and downregulates the expression of downstream genes VEGF, MMP7 and MMP9. HSP110-IN-1 abrogates IL-6-induced epithelial-mesenchymal transition and inhibits the proliferation of colorectal cancer cells. HSP110-IN-1 remodels the tumor microenvironment by inducing a pro-inflammatory phenotype, regulates macrophages, induces PD-L1 expression, and enhances anti-PD-L1 antibody-mediated tumor regression. HSP110-IN-1 can be used in studies related to colorectal cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HSP110-IN-1 | HSP110-IN-1 is a HSP110 inhibitor. HSP110-IN-1 binds to HSP110, inhibits the activity of STAT3, and downregulates the expression of downstream genes VEGF, MMP7 and MMP9. HSP110-IN-1 abrogates IL-6-induced epithelial-mesenchymal transition and inhibits the proliferation of colorectal cancer cells. HSP110-IN-1 remodels the tumor microenvironment by inducing a pro-inflammatory phenotype, regulates macrophages, induces PD-L1 expression, and enhances anti-PD-L1 antibody-mediated tumor regression. HSP110-IN-1 can be used in studies related to colorectal cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Xu L, et al. Discovery of second generation heat shock protein 110 (HSP110) inhibitors for potential treatment of Colorectal cancer. European Journal of Medicinal Chemistry Reports. 2023 Apr 1;7:100103.
- [2]. Abrey-Recalde MJ, et al. Combining PD-L1 blockade with a second-generation HSP110 inhibitor enhances antitumor immunity in colorectal cancer. Cell Death Dis. Published online May 19, 2026. [Content Brief]
